Semler Scientific, Inc.
semlerscientific.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 12, 2025. Its latest SEC filing is a SCHEDULE 13G/A from May 11, 2026.
10-Q for Q3 FY2025, filed Nov 12, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells QuantaFlo, a blood-flow testing product that helps internists and cardiovascular specialists assess peripheral artery disease.
10-K for FY2024, filed Feb 28, 2025
How Did They Make Money?
Customers license QuantaFlo for a fixed monthly fee, usually paid in advance for the next month, or a variable monthly fee based on tests; some pay quarterly or annually in advance. The company also sells QuantaFlo equipment and accessories.
10-K for FY2024, filed Feb 28, 2025
$56.3M
-
10-K for FY2024, filed Feb 28, 2025
$56.3M ↗
Who Were Their Customers?
Semler's salespeople sell QuantaFlo directly to healthcare providers, including internists and cardiovascular specialists, and provide training online or in person.
10-K for FY2024, filed Feb 28, 2025We provide our QuantaFlo product and any other products for which we have distribution rights to our customers through our salespersons…View ↗
We deliver QuantaFlo directly to our customers, and in-service training to the customers is provided either on-line or in person. Because…View ↗
Our intention is to provide a tool to internists and non-cardiovascular experts, for whom it was previously impractical to conduct a blood…View ↗
10-K for FY2024, filed Feb 28, 2025
Management periodically monitors the creditworthiness of its customers and believes that it has adequately provided for any exposure to…View ↗
Did Revenues Turn Into Profits?
Yes. It kept 73 cents of every revenue dollar as net income in FY2024 and turned 43 cents into free cash flow.
10-K for FY2024, filed Feb 28, 2025
$20.9MView ↗
10-K for FY2024, filed Feb 28, 2025
$40.9MView ↗
10-K for FY2024, filed Feb 28, 2025
$24.4MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 12, 2025
$16.9MView ↗
- ▲ +201%
- vs $5.6M in Q3 FY2024
-
Jan 16, 2026
Completes merger with Strive
Each Semler share converted into the right to receive 21.05 Strive shares.
Sources
8-K, filed Jan 16, 2026
Upon the completion of the Merger, Semler Scientific, Strive and U.S Trust Company, National Association, as trustee, entered into a…View ↗
-
Oct 17, 2025
CFO resigned; CEO appointed interim CFO
Renae Cormier resigned as CFO, and CEO Douglas Murphy-Chutorian took on the interim role.
Sources
8-K, filed Oct 17, 2025
On October 16, 2025, Renae Cormier resigned from her position as Chief Financial Officer (and as principal financial officer and principal…View ↗
-
Oct 3, 2025
Warns fourth-quarter revenue will be at least 60% lower
A customer representing more than 10% of revenue stopped using QuantaFlo; the comparison is with expected third-quarter revenue.
Sources
8-K, filed Oct 3, 2025
Semler Scientific previously reported that it is experiencing and expects to continue to experience decreased usage of its QuantaFlo device…View ↗
Grew. Revenue grew 46% in 4 years, from $38.6M in FY2020 to $56.3M in FY2024, about 10% a year.
Loading...
